Marie Asano

Partner

Stéphane Roussel

Partner

Michael Nettersheim Ph.D

Managing Partner

7 past transactions

Biosyntia

Series B in 2022
Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology. By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds by fermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow. Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.

In Ovo

Series B in 2022
In Ovo combines animal welfare and efficiency by offering biotechnological solutions to the poultry industry. We currently focus on a long existing problem in hatcheries: The culling of one day old male chickens. Our solution, a gender screening in the first half of the breeding process, has several advantages. It prevents a lot of stress the chickens experience during the current manual gender sorting process, it reduces the energy consumption and CO2 emission of the hatchery and prevents the need to kill one day old chickens. This way, we make hatcheries more animal friendly and sustainable, and increase the efficiency at the same time.

Protix

Private Equity Round in 2022
Protix is an industrial-scale producer of quality insect proteins and lipids to feed animals and accelerate the transition to a food system in balance with nature.

Elicit Plant

Series A in 2022
Elicit Plant is an agro-biotech company specializing in crops’ water resistance and the development of innovative phytosterol-based solutions. The company develops products that significantly reduce water stress in field-grown plants, making them better equipped to handle water shortages.

Nuritas

Series B in 2021
Nuritas is revolutionising the discovery of novel, natural and scientifically proven active ingredients that can manage and improve human health. The company’s disruptive computational approach to discovery uses artificial intelligence and genomics to, for the first time ever, rapidly and efficiently predict and then provide access to the most health-benefiting components hidden within food, called bioactive peptides.

Aphea.Bio

Series B in 2021
Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.

Aphea.Bio

Series B in 2020
Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.